Neoadjuvant endocrine therapy versus neoadjuvant chemotherapy in node-positive invasive lobular carcinoma

BACKGROUND: Neoadjuvant chemotherapy (NACT) is often recommended for patients with node-positive invasive lobular carcinoma (ILC) despite unclear benefit in this largely hormone receptor-positive (HR+) group. We sought to compare overall survival (OS) between patients with node-positive ILC who rece...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Ann Surg Oncol
Hlavní autoři: Thornton, MJ, Williamson, HV, Westbrook, KE, Greenup, RA, Plichta, JK, Rosenberger, LH, Gupta, A, Hyslop, T, Hwang, ES, Fayanju, OM
Médium: Artigo
Jazyk:Inglês
Vydáno: 2019
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6736696/
https://ncbi.nlm.nih.gov/pubmed/31342392
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1245/s10434-019-07564-9
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky